December 2017 Investor Update Presentation Visuals

Click on image above or here to download presentation visuals for December 2017 investor update. (2MB pdf)


Investor Conference Call

Imagion Biosystems Limited (Imagion, ASX:IBX) invites shareholders and other interested parties to join CEO Robert Proulx for an update on the company's…


Appendix 4C for Q3 2017

In accord with ASX requirements, Imagion Biosystems has lodged "Appendix 4C, Quarterly report for entities subject to Listing Rule 4.7B" for the Quarter ended…


Investor Update — Corporate Presentation Visuals

Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content…


Imagion Biosystems Secures Nanoparticle Manufacturer

Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Master Service Agreement with ChemConnection BV, a Dutch contract manufacturing organization…



Notice: Undefined index: file in /nas/content/live/imagionbx/wp-includes/media.php on line 1675

Imagion Biosystems Initiates MagSense® Instrument Development

Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Service Agreement with StarFish Medical ("StarFish"), Canada's largest medical device design,…


Appendix 4C for Q2 2017

In accord with ASX requirements, Imagion Biosystems' quarterly financial statement Appendix 4C was lodged with the Australian Securities Exchange on 31 July,…


Imagion Biosystems Identifies Key Operational Objectives

Imagion Biosystems Limited (Imagion, ASX:IBX), is pleased to provide shareholders and interested parties an outline of its operational objectives as it moves…


Initial Director's Interest Notice

View the Initial Director's Interest Notice.


Imagion Biosystems Raises A$12 million in Initial Public Offering

Imagion Biosystems is now a publicly traded company after completing a heavily supported A$12 million initial public offering (IPO) on the Australian…